Epinephrine nasal spray approved by FDA

The U.S. Food and Drug Administration has approved epinephrine nasal spray for the emergency treatment of allergic reactions such as anaphylaxis in adult and pediatric patients weighing at least 66 pounds.

Approval of the novel nasal spray was based on four studies in 175 healthy patients without anaphylaxis. Researchers measured epinephrine concentrations in the blood following administration of the spray or epinephrine injectable products. They found that the epinephrine nasal spray had comparable epinephrine blood concentrations and similar increases in blood pressure and heart rate as the injectable products.

The researchers hope the FDA approval can help reduce barriers to the rapid treatment of anaphylaxis, particularly among pediatric patients who may delay or avoid treatment out of fear of injections.

Read more: FDA

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.